Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANOFI INDIA Dec-17 |
ADCOCK INGRAM Jun-14 |
SANOFI INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,945 | 368 | - | |
Low | Rs | 3,901 | 265 | - | |
Sales per share (Unadj.) | Rs | 1,081.8 | 109.3 | - | |
Earnings per share (Unadj.) | Rs | 141.6 | -27.6 | - | |
Cash flow per share (Unadj.) | Rs | 185.9 | -22.8 | - | |
Dividends per share (Unadj.) | Rs | 33.00 | 0 | - | |
Dividend yield (eoy) | % | 0.7 | 0 | - | |
Book value per share (Unadj.) | Rs | 868.8 | 85.8 | - | |
Shares outstanding (eoy) | m | 23.03 | 168.78 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.1 | 2.9 | 141.3% | |
Avg P/E ratio | x | 31.2 | -11.5 | -272.1% | |
P/CF ratio (eoy) | x | 23.8 | -13.9 | -171.7% | |
Price / Book Value ratio | x | 5.1 | 3.7 | 138.1% | |
Dividend payout | % | 23.3 | 0 | - | |
Avg Mkt Cap | Rs m | 101,862 | 53,397 | 190.8% | |
No. of employees | `000 | 3.2 | 4.3 | 75.4% | |
Total wages/salary | Rs m | 3,685 | 3,351 | 110.0% | |
Avg. sales/employee | Rs Th | 7,691.9 | 4,298.8 | 178.9% | |
Avg. wages/employee | Rs Th | 1,137.7 | 780.6 | 145.7% | |
Avg. net profit/employee | Rs Th | 1,006.5 | -1,083.2 | -92.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 24,914 | 18,455 | 135.0% | |
Other income | Rs m | 807 | 129 | 624.4% | |
Total revenues | Rs m | 25,721 | 18,584 | 138.4% | |
Gross profit | Rs m | 5,372 | -3,198 | -168.0% | |
Depreciation | Rs m | 1,022 | 796 | 128.3% | |
Interest | Rs m | 11 | 500 | 2.2% | |
Profit before tax | Rs m | 5,146 | -4,365 | -117.9% | |
Minority Interest | Rs m | 0 | -12 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,886 | 273 | 691.4% | |
Profit after tax | Rs m | 3,260 | -4,650 | -70.1% | |
Gross profit margin | % | 21.6 | -17.3 | -124.4% | |
Effective tax rate | % | 36.6 | -6.2 | -586.5% | |
Net profit margin | % | 13.1 | -25.2 | -51.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 14,432 | 13,517 | 106.8% | |
Current liabilities | Rs m | 6,010 | 7,605 | 79.0% | |
Net working cap to sales | % | 33.8 | 32.0 | 105.5% | |
Current ratio | x | 2.4 | 1.8 | 135.1% | |
Inventory Days | Days | 61 | 111 | 54.9% | |
Debtors Days | Days | 28 | 124 | 23.0% | |
Net fixed assets | Rs m | 7,991 | 7,879 | 101.4% | |
Share capital | Rs m | 230 | 86 | 268.8% | |
Net worth | Rs m | 20,008 | 14,485 | 138.1% | |
Long term debt | Rs m | 0 | 5,090 | 0.0% | |
Total assets | Rs m | 27,770 | 27,363 | 101.5% | |
Interest coverage | x | 468.8 | -7.7 | -6,063.2% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.7 | 133.0% | |
Return on assets | % | 11.8 | -15.2 | -77.7% | |
Return on equity | % | 16.3 | -32.1 | -50.8% | |
Return on capital | % | 25.8 | -19.8 | -130.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,351 | 1,575 | 276.2% | |
From Investments | Rs m | -787 | -484 | 162.7% | |
From Financial Activity | Rs m | -1,884 | 4,620 | -40.8% | |
Net Cashflow | Rs m | 1,680 | 5,711 | 29.4% |
Compare SANOFI INDIA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SANOFI INDIA With: CIPLA AJANTA PHARMA SUVEN LIFE AUROBINDO PHARMA FDC LTD.
| |
Indian share markets continued their momentum during closing hours and ended the day on a positive note. Gains were largely seen in the metal sector and healthcare sector.
For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Should you subscribe to the IPO of Shalby Ltd?
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsThe real estate sector is ready to make a comeback. This is the stock to consider buying.
During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
This is the trick to following super investors and not losing money.
Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More
| |